Company Quick10K Filing
INmune Bio
10-K 2019-12-31 Filed 2020-03-11
10-Q 2019-09-30 Filed 2019-11-08
S-1 2019-07-18 Public Filing
10-Q 2019-06-30 Filed 2019-08-09
S-1 2019-06-21 Public Filing
10-Q 2019-03-31 Filed 2019-05-15
10-K 2018-12-31 Filed 2019-03-29
S-1 2018-08-30 Public Filing
8-K 2020-05-11 Other Events, Exhibits
8-K 2020-05-06 Other Events, Exhibits
8-K 2020-05-05 Other Events, Exhibits
8-K 2020-04-28 Other Events, Exhibits
8-K 2020-04-23 Other Events, Exhibits
8-K 2020-04-22 Other Events, Exhibits
8-K 2020-04-20 Other Events, Exhibits
8-K 2020-04-20 Other Events, Exhibits
8-K 2020-04-16 Exhibits
8-K 2020-04-09 Regulation FD, Exhibits
8-K 2020-03-11 Earnings, Exhibits
8-K 2020-03-05 Regulation FD, Exhibits
8-K 2020-02-27 Regulation FD, Exhibits
8-K 2020-02-04 Enter Agreement, Regulation FD, Exhibits
8-K 2020-01-23 Enter Agreement, Exhibits
8-K 2020-01-13 Regulation FD, Exhibits
8-K 2020-01-02 Regulation FD, Exhibits
8-K 2019-12-17 Regulation FD, Exhibits
8-K 2019-12-02 Regulation FD, Exhibits
8-K 2019-11-25 Sale of Shares, Officers, Other Events, Exhibits
8-K 2019-11-18 Officers, Other Events, Exhibits
8-K 2019-11-08 Earnings, Exhibits
8-K 2019-10-16 Regulation FD, Exhibits
8-K 2019-10-08 Regulation FD, Exhibits
8-K 2019-09-23 Regulation FD, Exhibits
8-K 2019-09-16 Regulation FD, Exhibits
8-K 2019-09-12 Regulation FD, Exhibits
8-K 2019-09-12 Shareholder Vote
8-K 2019-09-09 Regulation FD, Exhibits
8-K 2019-09-04 Regulation FD, Exhibits
8-K 2019-08-27 Regulation FD, Exhibits
8-K 2019-08-14 Regulation FD, Exhibits
8-K 2019-08-12 Earnings, Exhibits
8-K 2019-08-05 Regulation FD, Exhibits
8-K 2019-08-05 Officers, Exhibits
8-K 2019-08-01 Regulation FD, Exhibits
8-K 2019-07-25 Regulation FD, Exhibits
8-K 2019-07-08 Other Events
8-K 2019-07-03 Regulation FD, Exhibits
8-K 2019-06-27 Regulation FD, Exhibits
8-K 2019-06-26 Regulation FD, Exhibits
8-K 2019-06-21 Regulation FD, Exhibits
8-K 2019-06-19 Regulation FD, Exhibits
8-K 2019-06-11 Regulation FD, Exhibits
8-K 2019-06-04 Regulation FD, Exhibits
8-K 2019-05-30
8-K 2019-05-28 Regulation FD, Exhibits
8-K 2019-05-20 Enter Agreement, Exhibits
8-K 2019-05-16 Enter Agreement, Exhibits
8-K 2019-05-15 Enter Agreement, Earnings, Sale of Shares, Regulation FD, Exhibits
8-K 2019-05-07 Enter Agreement, Sale of Shares, Regulation FD, Exhibits
8-K 2019-04-30 Enter Agreement, Sale of Shares
8-K 2019-04-24 Other Events, Exhibits
8-K 2019-04-17 Other Events, Exhibits
8-K 2019-04-12 Other Events, Exhibits
8-K 2019-04-02 Other Events, Exhibits
8-K 2019-03-11 Regulation FD, Exhibits
8-K 2019-02-22 Enter Agreement, Other Events, Exhibits
8-K 2019-02-11 Regulation FD, Exhibits
8-K 2019-02-08 Regulation FD, Exhibits
8-K 2019-02-06 Regulation FD, Exhibits
8-K 2019-02-01 Enter Agreement, Regulation FD, Exhibits
8-K 2019-01-15 Regulation FD, Exhibits

INmune Bio Financials

INMB Metrics, Comps, Filings

Quarterly | Annual

Business

Our objective is to develop and commercialize our product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. This can be in cancer where Natural Killer ("NK") cells are inactive and contribute to a tumor's evasion of the immune system and/or disease progression while Myeloid Derived Suppressor Cells ("MDSC") proliferate to protect the tumor from attack by the patient's immune system or this can be other diseases such as neurologic and metabolic diseases where chronic inflammation results in innate immune system dysfunction and disease progression. Our initial focus will be the treatment of cancer solid tumors and treatment of Alzheimer's Disease. In cancer, we plan to pursue two parallel development programs: (1) with INKmune our first drug candidate, we will initially focus on treating women with relapse refractory ovarian carcinoma; (2) with INB03, we will treat patients with advanced cancers with elevated biomarkers of inflammation including elevated levels of MDSC in their blood. Our third drug candidate XPro1595, targets Alzheimer's Disease which we initiated once we received a non-dilutive funding from the Alzheimer's Association as a $1 million US dollar Part-the-Cloud Award (as described below). Once resources are available, we intend to expand our development programs with INKmune, INB03 and XPro1595 into high risk Myelodysplastic Syndromes ("MDS"), a combination therapy trial with approved checkpoint inhibitors in patients with resistant or refractory to checkpoint inhibitors and other neurodegenerative diseases respectively. The principal components of our strategy to achieve this objective are to:

Copy History · pursue development strategies and regulatory approval pathways that allow the treatment of oncology patients with our lead product candidates, INKmune and INB03; · pursue development strategies and regulatory approval pathways that allow the treatment of neurodegenerative diseases in patients with our lead product candidates, XPro1595; · adopt a product development strategy that solidifies our existing intellectual property ("IP") to prevent competition and expand our IP suite into related immunotherapeutic areas; · provide clear value propositions to third-party payers, such as managed care companies or government programs like Medicare, to merit reimbursement for our product candidates; and · enter into collaborations with other pharmaceutical companies with respect to, among other things, our INKmune and INB03 product candidates and other products that will benefit from development or marketing beyond our current resources.

Pursue development and regulatory approval pathways. We believe INKmune, INB03 and XPro1595 may be approvable under pathways that are potentially shorter than those typically available for drug products based on novel active ingredients, including as an orphan drug under the Orphan Drug Act and approval under the Food and Drug Administration (the "FDA") Accelerated Approval Program (see "Government Regulation"). We have not yet had a discussion with the Medicines and Healthcare Products Regulatory Agency ("MHRA") and/or FDA regarding such designation, but plan to do so in 2019. We believe both our high risk MDS and ovarian carcinoma treatment programs fit the criteria used by the FDA to grant these regulatory designations. We believe that it would take a minimum of six months to receive Orphan Drug status once we submit an application and a minimum of 12 months to receive a designation once we submit an application. We might never have these discussions, submit applications under the Orphan Drug Act as the FDA Accelerated Approval Program or have these applications approved if we do.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Integrity Applications (IGAP) 64,825 0% -72.7 -44% 1,974 2,836 140 0 -874 -874 63,546
Radisys (RSYS) 64,574 27% -97.1 -33% 57,835 65,385 109,918 29,205 -19,359 -578 56,127
Peoples Financial (PFBX) 64,261 11.4 0% 617,489 523,162 0 0 553 3,135 35,782
Electrum Special Acquisition (ELECU) 64,124 -356.8 -0% 128,485 11,837 0 0 -180 -180 64,096
Summer Energy (SUME) 63,005 9% -19.8 -9% 60,900 51,472 130,021 11,888 -5,619 -3,470 68,685
Sonim Technologies (SONM) 62,906 32% -3.4 -28% 68,973 40,342 99,081 31,437 -19,057 -16,692 56,855
Cryo Cell (CCEL) 62,661 68% 27.7 1% 40,889 48,983 23,494 15,913 575 2,439 67,644
I-On Communications (ALES) 62,354 20% -80.0 -13% 8,863 2,470 5,283 1,043 -1,111 -758 60,670
Nephros (NEPH) 62,276 58% -14.8 -38% 11,554 4,832 8,942 5,182 -4,384 -4,006 59,300
Kaanapali Land (KANP) 62,158 7% -9.8 -3% 106,294 24,515 4,885 364 -2,988 -3,678 36,038
Imprimis Pharmaceuticals (IMMY) 62,078 77% -27.3 -14% 28,289 23,836 29,988 23,163 -4,097 -2,510 68,431
INmune Bio (INMB) 61,884 -10.2 -21% 25,396 687 0 0 -5,360 -5,360 54,502
Santa Fe Gold (SFEG) 61,079 6.6 729% 1,228 15,246 0 0 8,947 9,931 65,322
Emarine Global (EMRN) 60,630 48% 1.5 4% 3,475,740 7,588,357 3,595,221 1,725,943 123,731 400,532 611,829
iWeb (IWBB) 60,297 -109.5 -40% 1,355 222 0 0 -548 -546 59,715
Lightwave Logic (LWLG) 59,578 -9.9 -99% 6,603 1,842 0 0 -6,508 -5,828 57,410
China Health Industries (CHHE) 58,986 75% 4.3 8% 44,808 8,362 9,187 6,914 3,431 5,600 24,004
Research Solutions (RSSS) 58,660 30% -66.0 -8% 10,500 7,483 29,437 8,712 -864 -804 53,072
Mateon Therapeutics (OXGN) 58,429 -21.4 -37% 7,529 2,728 0 0 -2,813 -2,725 58,413
Aerogrow (AERO) 58,358 33% -28.0 -12% 20,938 10,670 30,944 10,128 -2,487 -2,210 61,797

Balance Sheet ($'000)2018-12-312019-03-312019-06-302019-09-30
Cash1866,0499,3647,383
Accounts Receivable
Inventory
PP&E
Assets17,36323,64527,53025,396
Accounts Payable
Long-Term Debt
Liabilities824781693687
Stockholders' Equity16,54022,86426,83724,709
Income Statement ($'000)2018-12-312019-03-312019-06-302019-09-30
Revenue000
Cost of Revenue
Gross Profit
R&D1022941,168
SG&A1,8091,6771,916
Tax000
Net Income-1,901-392-3,067
Cash Flow ($'000)2018-12-312019-03-312019-06-302019-09-30
Cash Operating-1,388-1,618-1,946
Cash Investing
Cash Financing7,2514,9580